{"id":32979,"date":"2025-05-07T14:26:27","date_gmt":"2025-05-07T06:26:27","guid":{"rendered":"https:\/\/flcube.com\/?p=32979"},"modified":"2025-05-07T14:26:28","modified_gmt":"2025-05-07T06:26:28","slug":"zhongsheng-pharmas-ray1225-shows-positive-results-in-phase-ii-trials-for-weight-loss-and-blood-glucose-reduction","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32979","title":{"rendered":"Zhongsheng Pharma&#8217;s RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction"},"content":{"rendered":"\n<p>China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/002317:SHE\">SHE: 002317<\/a>) announced positive top-line analysis results from dose expansion cohorts of two Phase II clinical studies for its Category 1 innovative polypeptide drug candidate RAY1225, targeting weight loss and blood glucose reduction. The preliminary results indicated that RAY1225 injection (3\u20139 mg) demonstrated positive efficacy and favorable safety profiles in Chinese adult obese\/overweight participants and type 2 diabetes patients, achieving ideal results that met the expected goals.<\/p>\n\n\n\n<p><strong>RAY1225 Mechanism and Trial Design<\/strong><br>RAY1225 is a long-acting glucagon-like peptide-1 (GLP-1) drug with dual activation activity of the GLP-1 receptor and glucose-dependent insulin-promoting polypeptide (GIP) receptor. The Phase II trial (REBUILDING-1) in obese\/overweight patients and the Phase II trial (SHINING-1) in type 2 diabetes patients each comprised Part A (parallel study: 3 mg, 6 mg, and placebo groups) and Part B (dose escalation and expansion study: 9 mg escalation group and expansion group). Both trials met their primary endpoints, recently completed data cleaning and locking for the dose expansion cohorts, and obtained top-line analysis results.<\/p>\n\n\n\n<p><strong>Clinical Trial Results<\/strong><br>RAY1225 injection demonstrated significant superiority over placebo in weight loss, blood glucose control, and improvement of cardiovascular, renal, and metabolic risk factors. These results highlight the potential of RAY1225 as a promising treatment option for obesity and type 2 diabetes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/\u4f17\u751f\u836f\u4e1a\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u4e00\u7c7b\u521b\u65b0\u836fRAY1225\u6ce8\u5c04\u6db2II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u83b7\u5f97\u9876\u7ebf\u5206\u6790\u6570\u636e\u7ed3\u679c\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u4f17\u751f\u836f\u4e1a\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u4e00\u7c7b\u521b\u65b0\u836fRAY1225\u6ce8\u5c04\u6db2II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u83b7\u5f97\u9876\u7ebf\u5206\u6790\u6570\u636e\u7ed3\u679c\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-9aaa8969-5195-41e1-b805-85440458fa28\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/\u4f17\u751f\u836f\u4e1a\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u4e00\u7c7b\u521b\u65b0\u836fRAY1225\u6ce8\u5c04\u6db2II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u83b7\u5f97\u9876\u7ebf\u5206\u6790\u6570\u636e\u7ed3\u679c\u7684\u516c\u544a.pdf\">\u4f17\u751f\u836f\u4e1a\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u4e00\u7c7b\u521b\u65b0\u836fRAY1225\u6ce8\u5c04\u6db2II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u83b7\u5f97\u9876\u7ebf\u5206\u6790\u6570\u636e\u7ed3\u679c\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/\u4f17\u751f\u836f\u4e1a\uff1a\u5173\u4e8e\u63a7\u80a1\u5b50\u516c\u53f8\u4e00\u7c7b\u521b\u65b0\u836fRAY1225\u6ce8\u5c04\u6db2II\u671f\u4e34\u5e8a\u8bd5\u9a8c\u83b7\u5f97\u9876\u7ebf\u5206\u6790\u6570\u636e\u7ed3\u679c\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9aaa8969-5195-41e1-b805-85440458fa28\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line analysis results from dose&#8230;<\/p>\n","protected":false},"author":1,"featured_media":32981,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,39,86,1197,399],"class_list":["post-32979","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-diabetes","tag-obesity","tag-she-002317","tag-zhongsheng-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zhongsheng Pharma&#039;s RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line analysis results from dose expansion cohorts of two Phase II clinical studies for its Category 1 innovative polypeptide drug candidate RAY1225, targeting weight loss and blood glucose reduction. The preliminary results indicated that RAY1225 injection (3\u20139 mg) demonstrated positive efficacy and favorable safety profiles in Chinese adult obese\/overweight participants and type 2 diabetes patients, achieving ideal results that met the expected goals.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32979\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhongsheng Pharma&#039;s RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction\" \/>\n<meta property=\"og:description\" content=\"China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line analysis results from dose expansion cohorts of two Phase II clinical studies for its Category 1 innovative polypeptide drug candidate RAY1225, targeting weight loss and blood glucose reduction. The preliminary results indicated that RAY1225 injection (3\u20139 mg) demonstrated positive efficacy and favorable safety profiles in Chinese adult obese\/overweight participants and type 2 diabetes patients, achieving ideal results that met the expected goals.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32979\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-07T06:26:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-07T06:26:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0712.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32979#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32979\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhongsheng Pharma&#8217;s RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction\",\"datePublished\":\"2025-05-07T06:26:27+00:00\",\"dateModified\":\"2025-05-07T06:26:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32979\"},\"wordCount\":230,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32979#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0712.webp\",\"keywords\":[\"Clinical trial results\",\"Diabetes\",\"Obesity\",\"SHE: 002317\",\"Zhongsheng Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32979#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32979\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32979\",\"name\":\"Zhongsheng Pharma's RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32979#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32979#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0712.webp\",\"datePublished\":\"2025-05-07T06:26:27+00:00\",\"dateModified\":\"2025-05-07T06:26:28+00:00\",\"description\":\"China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line analysis results from dose expansion cohorts of two Phase II clinical studies for its Category 1 innovative polypeptide drug candidate RAY1225, targeting weight loss and blood glucose reduction. The preliminary results indicated that RAY1225 injection (3\u20139 mg) demonstrated positive efficacy and favorable safety profiles in Chinese adult obese\\\/overweight participants and type 2 diabetes patients, achieving ideal results that met the expected goals.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32979#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32979\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32979#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0712.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0712.webp\",\"width\":1080,\"height\":608,\"caption\":\"Zhongsheng Pharma's RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32979#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhongsheng Pharma&#8217;s RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhongsheng Pharma's RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line analysis results from dose expansion cohorts of two Phase II clinical studies for its Category 1 innovative polypeptide drug candidate RAY1225, targeting weight loss and blood glucose reduction. The preliminary results indicated that RAY1225 injection (3\u20139 mg) demonstrated positive efficacy and favorable safety profiles in Chinese adult obese\/overweight participants and type 2 diabetes patients, achieving ideal results that met the expected goals.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32979","og_locale":"en_US","og_type":"article","og_title":"Zhongsheng Pharma's RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction","og_description":"China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line analysis results from dose expansion cohorts of two Phase II clinical studies for its Category 1 innovative polypeptide drug candidate RAY1225, targeting weight loss and blood glucose reduction. The preliminary results indicated that RAY1225 injection (3\u20139 mg) demonstrated positive efficacy and favorable safety profiles in Chinese adult obese\/overweight participants and type 2 diabetes patients, achieving ideal results that met the expected goals.","og_url":"https:\/\/flcube.com\/?p=32979","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-07T06:26:27+00:00","article_modified_time":"2025-05-07T06:26:28+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0712.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32979#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32979"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhongsheng Pharma&#8217;s RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction","datePublished":"2025-05-07T06:26:27+00:00","dateModified":"2025-05-07T06:26:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32979"},"wordCount":230,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32979#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0712.webp","keywords":["Clinical trial results","Diabetes","Obesity","SHE: 002317","Zhongsheng Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32979#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32979","url":"https:\/\/flcube.com\/?p=32979","name":"Zhongsheng Pharma's RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32979#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32979#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0712.webp","datePublished":"2025-05-07T06:26:27+00:00","dateModified":"2025-05-07T06:26:28+00:00","description":"China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line analysis results from dose expansion cohorts of two Phase II clinical studies for its Category 1 innovative polypeptide drug candidate RAY1225, targeting weight loss and blood glucose reduction. The preliminary results indicated that RAY1225 injection (3\u20139 mg) demonstrated positive efficacy and favorable safety profiles in Chinese adult obese\/overweight participants and type 2 diabetes patients, achieving ideal results that met the expected goals.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32979#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32979"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32979#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0712.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0712.webp","width":1080,"height":608,"caption":"Zhongsheng Pharma's RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32979#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhongsheng Pharma&#8217;s RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0712.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32979","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32979"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32979\/revisions"}],"predecessor-version":[{"id":32982,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32979\/revisions\/32982"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32981"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32979"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32979"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32979"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}